| Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the most aggressive clinical state of prostate cancer, represents a significant burden on the healthcare system. Both healthcare resource utilization (HCRU) and costs are higher in the mCRPC setting than in the nonmetastatic (nmCRPC) setting. |
| Improvements in the care and management of patients with nmCRPC may mitigate a portion of this healthcare burden and subsequent cost of care. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.